跳到正文
原文
STAT 主站· Meghana Keshavan and Brittany Trang·· 11 天前AI 评分35

Vir Biotechnology 两款药物治疗乙型肝炎 D 病毒 III 期试验成功

STAT+: Gene therapy’s long-debated cancer risk materializes

AI 导读

Vir Biotechnology 的两款药物在 III 期试验中使 44% 的乙型肝炎 D 病毒患者病毒水平降至不可检测水平,达到主要研究终点。Zura Bio 的抗体药物 tibulizumab 在治疗 hidradenitis suppurativa 的中期试验中未显示出优于安慰剂的效果。

正文

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The tumors possibly connected to pediatric gene therapies make me sad. Babies. 

The need-to-know this morning

  • Vir Biotechnology said monthly injections of two experimental medicines reduced hepatitis D virus to undetectable levels in 44% of patients compared to none of the patients who received delayed treatment with the same regimen. The result achieved the primary goal of a Phase 3 study. 
  • Zura Bio said its experimental antibody tibulizumab failed to improve the symptoms of hidradenitis suppurativa, an inflammatory skin condition, compared to a placebo in a mid-stage study. 
  • Roivant said Lisraya generated $31 million in sales in the five weeks since it was approved to treat dermatomyositis.
  • Argenx is acquiring privately held Unnatural Products, a medicinal chemistry company that specializes in the discovery of protein-based drugs. 

Why two heart trials should puncture AI drug discovery enthusiasm

Before anyone promises that AI will cure every disease, consider what happened the last time a shiny new tool was supposed to make drug development more predictable. At the American Heart Association meeting, two big trials came up empty.

Continue to STAT+ to read the full story…

来源:STAT 主站 · statnews.com